Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway
Junlong Zhu, Aimin Wang, Hang Tong, Yan Sun, Tinghao Li, Linfeng Wu, Xiaoyu Zhang, Zijia Qin, Weiyang He · 2026
Read Abnormal Sialylation Promotes Chemotherapy Resistance in Bladder Cancer via the PI3K-AKT-mTOR Signaling Pathway by Junlong Zhu, Aimin Wang, Hang Tong, Yan Sun, Tinghao Li, Linfeng Wu, Xiaoyu Zhang, Zijia Qin, Weiyang He (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13255594.txt.
Description
Junlong Zhu and colleagues report a 2026 study of sialylation, a sugar coating process on cell surfaces, in bladder cancer drug resistance. Standard chemotherapy with gemcitabine and cisplatin helps many patients, yet tumors often recur or stop responding. The team investigated whether abnormal sialylation helps explain who fares worse.
Their analysis linked sialylation-related molecules to patient prognosis, features of the tissue around tumors, and resistance to chemotherapy. The trail led to a central growth pathway, PI3K-AKT-mTOR, which is known to drive cancer cell survival. The work stops short of a clinical test, since the findings need laboratory and patient validation. Still, the authors argue the sugar-coating machinery deserves attention as a source of risk markers and future drug targets for this common urinary cancer.
Catalog record
| CREATOR | Junlong Zhu, Aimin Wang, Hang Tong, Yan Sun, Tinghao Li, Linfeng Wu, Xiaoyu Zhang, Zijia Qin, Weiyang He |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |